Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986166 DDI Study
NCT04956627Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of udifitimod in atopic dermatitis (AD) and ulcerative colitis (UC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Time of maximum observed plasma concentration and 7 more. Started Jul 2021; status: completed.
02
Drugs
udifitimod
03
Conditions
atopic dermatitis (AD)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04956627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956627.